Sugi Predict

Sugi Predict / Targets / UGCG

UGCG

Ceramide glucosyltransferase · Q16739 · UGCG on Sugi Atlas →

34,278 patent compounds predicted against UGCG, 18,363 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1088908 SCHEMBL1088908 0.67 20/20
SCHEMBL763368 SCHEMBL763368 0.75 17/20
SCHEMBL1085010 SCHEMBL1085010 0.79 16/20
SCHEMBL1088041 SCHEMBL1088041 0.69 16/20
SCHEMBL764354 SCHEMBL764354 0.78 15/20
SCHEMBL1088358 SCHEMBL1088358 0.71 15/20
SCHEMBL1088846 SCHEMBL1088846 0.71 15/20
SCHEMBL294652 SCHEMBL294652 1.00 14/20
SCHEMBL295736 SCHEMBL295736 1.00 14/20
SCHEMBL419334 SCHEMBL419334 1.00 14/20
Eliglustat Eliglustat (SCHEMBL420826) 1.00 14/20
Eliglustat Eliglustat (SCHEMBL421755) 1.00 14/20
SCHEMBL423128 SCHEMBL423128 1.00 14/20
SCHEMBL760628 SCHEMBL760628 1.00 14/20
SCHEMBL761669 SCHEMBL761669 1.00 14/20
SCHEMBL1085008 SCHEMBL1085008 1.00 14/20
SCHEMBL763366 SCHEMBL763366 0.79 14/20
SCHEMBL764374 SCHEMBL764374 0.75 14/20
SCHEMBL761681 SCHEMBL761681 1.00 13/20
SCHEMBL1009907 SCHEMBL1009907 0.54 13/20

Clinical trials — most relevant to UGCG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease PHASE4COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. PHASE2RECRUITING
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Miglustat on Gaucher Disease Type IIIB nanUNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C nanUNKNOWN
Registry Gangliosidoses nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS) nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors nanCOMPLETED
Omics Gaucher Study: Multiomic Approach nanACTIVE_NOT_RECRUITING
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Extracellular Vesicles, Insulin Action, and Exercise nanRECRUITING
Genetic Origin of Lipid Disorders nanUNKNOWN
Canadian Fabry Disease Initiative (CFDI) National Registry nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a UGCG binder may also engage these)

ProteinNameSimilarity
Q9R0E0 — 1.000 Q9R0E0 →
O88693 — 1.000 O88693 →
Q5BL38 — 1.000 Q5BL38 →
Q5U4S8 — 1.000 Q5U4S8 →
Q8AY29 — 1.000 Q8AY29 →
Q03562 — 0.988 Q03562 →
O01346 — 0.983 O01346 →
A8XAC4 — 0.982 A8XAC4 →
B1WB39 — 0.979 B1WB39 →
P13563 — 0.977 P13563 →
Q21054 — 0.972 Q21054 →
Q9D1E8 — 0.969 Q9D1E8 →
G4MS28 — 0.966 G4MS28 →
G5EC84 — 0.965 G5EC84 →
Q8S8S2 — 0.962 Q8S8S2 →
G5AY81 — 0.962 G5AY81 →
O57424 — 0.961 O57424 →
Q28265 — 0.961 Q28265 →
O18867 — 0.961 O18867 →
B7ZC96 — 0.961 B7ZC96 →
Q8R2Y0 — 0.960 Q8R2Y0 →
O57428 — 0.960 O57428 →
Q7SY73 — 0.960 Q7SY73 →
Q9UMX9 — 0.960 Q9UMX9 →
E9EFH8 — 0.960 E9EFH8 →
Q6GLL2 — 0.960 Q6GLL2 →
P17862 — 0.960 P17862 →
Q4LE88 — 0.960 Q4LE88 →
Q9BG98 — 0.959 Q9BG98 →
Q5ZJD8 — 0.959 Q5ZJD8 →